X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analysts have a “Moderate Buy” consensus on X4 Pharmaceuticals, with four buys, one hold and one sell among six analysts. The average 12-month price target is $11.25, versus the stock’s reported $2.81 price.
• Insiders sold 83,779 shares worth approximately $353,000 over the past 90 days, while institutional investors own 72.03% of the company.
• X4 exceeded quarterly expectations, reporting a loss of $0.13 per share versus the projected $0.18 loss and revenue of $8.81 million versus the $2.42 million estimate. Its primary product, FDA-approved XOLREMDI, treats WHIM syndrome.

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $11.25.

A number of analysts have commented on the company. Weiss Ratings upgraded X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 2nd. Wells Fargo & Company started coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an "overweight" rating and a $11.00 target price for the company.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, CFO David Kirske sold 11,767 shares of the business's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the sale, the chief financial officer owned 155,983 shares of the company's stock, valued at $446,111.38. The trade was a 7.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Adam Craig sold 47,436 shares of the firm's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $210,615.84. Following the transaction, the chairman directly owned 328,651 shares of the company's stock, valued at $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 83,779 shares of company stock worth $353,387 over the last 90 days. Corporate insiders own 1.13% of the company's stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several large investors have recently modified their holdings of XFOR. WINTON GROUP Ltd raised its holdings in shares of X4 Pharmaceuticals by 35.8% in the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company's stock worth $67,000 after buying an additional 3,800 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in X4 Pharmaceuticals in the 2nd quarter valued at $313,000. AXQ Capital LP acquired a new stake in X4 Pharmaceuticals in the 2nd quarter valued at $107,000. Wellington Management Group LLP bought a new stake in X4 Pharmaceuticals in the second quarter valued at $242,000. Finally, Bank of New York Mellon Corp bought a new stake in X4 Pharmaceuticals in the second quarter valued at $917,000. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $2.81 on Thursday. The firm has a market capitalization of $278.61 million, a PE ratio of -2.34 and a beta of 0.46. X4 Pharmaceuticals has a 1 year low of $2.70 and a 1 year high of $4.83. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. The firm's fifty day simple moving average is $3.74 and its 200 day simple moving average is $3.95.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.05. The firm had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. On average, sell-side analysts anticipate that X4 Pharmaceuticals will post -0.67 EPS for the current year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company's research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4's primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.